JMA van Gerven

662 total citations
17 papers, 529 citations indexed

About

JMA van Gerven is a scholar working on Cellular and Molecular Neuroscience, Cognitive Neuroscience and Pharmacology. According to data from OpenAlex, JMA van Gerven has authored 17 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 8 papers in Cognitive Neuroscience and 6 papers in Pharmacology. Recurrent topics in JMA van Gerven's work include Neuroscience and Neuropharmacology Research (5 papers), Sleep and Wakefulness Research (5 papers) and Sleep and related disorders (4 papers). JMA van Gerven is often cited by papers focused on Neuroscience and Neuropharmacology Research (5 papers), Sleep and Wakefulness Research (5 papers) and Sleep and related disorders (4 papers). JMA van Gerven collaborates with scholars based in Netherlands, France and United States. JMA van Gerven's co-authors include Rik C. Schoemaker, AF Cohen, Jan den Hartigh, Lineke Zuurman, J.L. Pinquier, Christine Le Roy, Kari L. Franson, Jasper Dingemanse, Julia Winkler and Robert Verpoorte and has published in prestigious journals such as SLEEP, Clinical Pharmacology & Therapeutics and Cephalalgia.

In The Last Decade

JMA van Gerven

17 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JMA van Gerven Netherlands 11 178 176 168 108 106 17 529
Pedro Araos Spain 18 270 1.5× 187 1.1× 90 0.5× 29 0.3× 30 0.3× 37 717
Christoph Felder United States 11 337 1.9× 40 0.2× 266 1.6× 65 0.6× 78 0.7× 15 677
Melissa J. Benson Australia 12 157 0.9× 306 1.7× 99 0.6× 20 0.2× 26 0.2× 18 603
Frank Enning Germany 11 130 0.7× 153 0.9× 137 0.8× 13 0.1× 105 1.0× 22 488
Peter van der Ark Belgium 12 87 0.5× 177 1.0× 201 1.2× 12 0.1× 157 1.5× 20 522
C. Albano Italy 14 304 1.7× 100 0.6× 80 0.5× 146 1.4× 38 0.4× 36 743
Nuria García‐Marchena Spain 15 182 1.0× 146 0.8× 54 0.3× 25 0.2× 29 0.3× 35 558
Matthew J. Pava United States 10 272 1.5× 214 1.2× 151 0.9× 15 0.1× 90 0.8× 11 486
Silke Conen Netherlands 11 61 0.3× 139 0.8× 97 0.6× 32 0.3× 14 0.1× 16 652
John Hamilton United States 13 262 1.5× 178 1.0× 57 0.3× 35 0.3× 57 0.5× 37 514

Countries citing papers authored by JMA van Gerven

Since Specialization
Citations

This map shows the geographic impact of JMA van Gerven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JMA van Gerven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JMA van Gerven more than expected).

Fields of papers citing papers by JMA van Gerven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JMA van Gerven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JMA van Gerven. The network helps show where JMA van Gerven may publish in the future.

Co-authorship network of co-authors of JMA van Gerven

This figure shows the co-authorship network connecting the top 25 collaborators of JMA van Gerven. A scholar is included among the top collaborators of JMA van Gerven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JMA van Gerven. JMA van Gerven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zuiker, Rob, et al.. (2023). Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers. Journal of Psychopharmacology. 37(6). 577–589. 2 indexed citations
2.
3.
Brooks, Stephen N., Justine Kent, Gabriël E. Jacobs, et al.. (2016). The orexin-2 antagonist JNJ-42847922 (MIN-202) improves sleep in patients with major depressive disorder (MDD) suffering from comorbid insomnia. European Neuropsychopharmacology. 26. S408–S409. 1 indexed citations
4.
5.
Dyck, Kristien Van, et al.. (2011). The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol. Journal of Psychopharmacology. 26(2). 282–291. 17 indexed citations
6.
Hoever, Petra, Julia Winkler, Rik C. Schoemaker, et al.. (2010). Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant. Clinical Pharmacology & Therapeutics. 87(5). 593–600. 85 indexed citations
7.
8.
Cruz, Hans G., Petra Hoever, Justin L. Hay, et al.. (2010). P.1.c.032 Interaction study between almorexant, a dual orexin receptor antagonist, and desipramine in healthy male subjects. European Neuropsychopharmacology. 20. S253–S253. 1 indexed citations
9.
Verschuuren, Jan J.G.M., JG van Dijk, Rik C. Schoemaker, et al.. (2009). Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clinical Pharmacology & Therapeutics. 86(1). 44–48. 91 indexed citations
10.
Rijk, Roel de, et al.. (2008). Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. Journal of Psychopharmacology. 22(4). 426–433. 14 indexed citations
11.
Zuurman, Lineke, et al.. (2008). Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. Journal of Psychopharmacology. 23(6). 633–644. 14 indexed citations
12.
Pelt, Jos van, et al.. (2008). Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. Journal of Psychopharmacology. 24(1). 65–72. 6 indexed citations
13.
Zuurman, Lineke, Christine Le Roy, Rik C. Schoemaker, et al.. (2008). Effect of intrapulmonary tetrahydrocannabinol administration in humans. Journal of Psychopharmacology. 22(7). 707–716. 121 indexed citations
14.
Zuurman, Lineke, Christine Le Roy, Rik C. Schoemaker, et al.. (2008). Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. Journal of Psychopharmacology. 24(3). 363–371. 40 indexed citations
15.
Franson, Kari L., et al.. (2008). Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. Journal of Psychopharmacology. 24(1). 73–82. 30 indexed citations
16.
Franson, Kari L., et al.. (2008). The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. Journal of Psychopharmacology. 23(6). 625–632. 56 indexed citations
17.
Post, Joris van der, Miranda T. Schram, Rik C. Schoemaker, et al.. (2002). Cns Effects of Sumatriptan and Rizatriptan in Healthy Female Volunteers. Cephalalgia. 22(4). 271–281. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Araos Breakdown of academic impact, for papers by Christoph Felder Breakdown of academic impact, for papers by Melissa J. Benson Breakdown of academic impact, for papers by Frank Enning Breakdown of academic impact, for papers by Peter van der Ark Breakdown of academic impact, for papers by C. Albano Breakdown of academic impact, for papers by Nuria García‐Marchena Breakdown of academic impact, for papers by Matthew J. Pava Breakdown of academic impact, for papers by Silke Conen Breakdown of academic impact, for papers by John Hamilton
Rankless by CCL
2026